ArticleFrontiers in oncology2026

Anlotinib plus penpulimab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the perspective of the Chinese healthcare system.

Gengliang Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.